Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis

BACKGROUND: Progressive bone marrow fibrosis (BMF) is a cardinal feature of many myeloproliferative neoplasms (MPNs) and there is a documented association between the severity of BMF and overall prognosis. We conducted an exploratory analysis of sequential BMF data from two phase I studies of long-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamieson, Catriona, Hasserjian, Robert, Gotlib, Jason, Cortes, Jorge, Stone, Richard, Talpaz, Moshe, Thiele, Jürgen, Rodig, Scott, Pozdnyakova, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566296/
https://www.ncbi.nlm.nih.gov/pubmed/26357842
http://dx.doi.org/10.1186/s12967-015-0644-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566296/
https://www.ncbi.nlm.nih.gov/pubmed/26357842
http://dx.doi.org/10.1186/s12967-015-0644-4

Ejemplares similares